[HTML][HTML] Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
M Wathikthinnakon, P Luangwattananun… - Scientific Reports, 2022 - nature.com
Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival.
Novel and more effective therapies than those currently available are, therefore, urgently …
Novel and more effective therapies than those currently available are, therefore, urgently …
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.
M Wathikthinnakon, P Luangwattananun… - Scientific …, 2022 - europepmc.org
Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival.
Novel and more effective therapies than those currently available are, therefore, urgently …
Novel and more effective therapies than those currently available are, therefore, urgently …
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
M Wathikthinnakon, P Luangwattananun… - Scientific …, 2022 - mahidol.elsevierpure.com
Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival.
Novel and more effective therapies than those currently available are, therefore, urgently …
Novel and more effective therapies than those currently available are, therefore, urgently …
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
M Wathikthinnakon, P Luangwattananun… - Scientific …, 2022 - ui.adsabs.harvard.edu
Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival.
Novel and more effective therapies than those currently available are, therefore, urgently …
Novel and more effective therapies than those currently available are, therefore, urgently …
[HTML][HTML] Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
M Wathikthinnakon, P Luangwattananun… - Scientific …, 2022 - ncbi.nlm.nih.gov
Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival.
Novel and more effective therapies than those currently available are, therefore, urgently …
Novel and more effective therapies than those currently available are, therefore, urgently …
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
M Wathikthinnakon, P Luangwattananun… - Scientific …, 2022 - pubmed.ncbi.nlm.nih.gov
Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival.
Novel and more effective therapies than those currently available are, therefore, urgently …
Novel and more effective therapies than those currently available are, therefore, urgently …
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
M Wathikthinnakon, P Luangwattananun… - Scientific …, 2022 - eprints.um.edu.my
Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival.
Novel and more effective therapies than those currently available are, therefore, urgently …
Novel and more effective therapies than those currently available are, therefore, urgently …
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.
M Wathikthinnakon, P Luangwattananun… - Scientific …, 2022 - search.ebscohost.com
Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival.
Novel and more effective therapies than those currently available are, therefore, urgently …
Novel and more effective therapies than those currently available are, therefore, urgently …
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
M Wathikthinnakon, P Luangwattananun… - Scientific …, 2022 - eprints.um.edu.my
Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival.
Novel and more effective therapies than those currently available are, therefore, urgently …
Novel and more effective therapies than those currently available are, therefore, urgently …